Navigation Links
New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes

phrol. 2001; 12:2735-8.

(6) Bakris G et al. Comparative long term effects of two AT1 receptor blockers on proteinuria in patients with type-2 diabetes and overt nephropathy and hypertension: results of the AMADEO trial.Presented at the Annual Meeting of the American Society of Hypertension. May 2007, Chicago, USA

(7) Burnier M, Brunner HR. Lancet 2000;355:637-45.

(8) Brunner HR. J Hum Hypertens 2002;16(suppl 2):S13-S16.

(9) Neutel JM, Smith HG. J Clin Hypertens 2003;5(1):58-63.

(10) Millar-Craig MW et al. Lancet 1978;1:795-97.

For further information: Dr. Reinhard Malin, Corporate Division Communications, Boehringer Ingelheim GmbH, 55216 Ingelheim/Germany, Phone: +49-6132 -77-90815, Fax: +49-6132-72-6601, E-mail: press@boehringer-ingelheim.com



'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments: